FR2704396A1 - Nutritional supplement which can be taken orally, intended for promoting the elimination of fats and the restoration of balanced nutritional behaviour - Google Patents
Nutritional supplement which can be taken orally, intended for promoting the elimination of fats and the restoration of balanced nutritional behaviour Download PDFInfo
- Publication number
- FR2704396A1 FR2704396A1 FR9305321A FR9305321A FR2704396A1 FR 2704396 A1 FR2704396 A1 FR 2704396A1 FR 9305321 A FR9305321 A FR 9305321A FR 9305321 A FR9305321 A FR 9305321A FR 2704396 A1 FR2704396 A1 FR 2704396A1
- Authority
- FR
- France
- Prior art keywords
- nutritional supplement
- vitamin
- elimination
- nutritional
- tyrosine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 235000015872 dietary supplement Nutrition 0.000 title claims abstract description 17
- 239000003925 fat Substances 0.000 title claims abstract description 12
- 230000008030 elimination Effects 0.000 title claims abstract description 7
- 238000003379 elimination reaction Methods 0.000 title claims abstract description 7
- 235000016709 nutrition Nutrition 0.000 title abstract 2
- 230000001737 promoting effect Effects 0.000 title 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 22
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims abstract description 19
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 16
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 11
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 11
- 239000011718 vitamin C Substances 0.000 claims abstract description 11
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 8
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 8
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 8
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 8
- 229940046009 vitamin E Drugs 0.000 claims abstract description 8
- 239000011709 vitamin E Substances 0.000 claims abstract description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims abstract description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims abstract description 5
- 239000011777 magnesium Substances 0.000 claims abstract description 5
- 229910052749 magnesium Inorganic materials 0.000 claims abstract description 5
- 235000001055 magnesium Nutrition 0.000 claims abstract description 5
- 235000002374 tyrosine Nutrition 0.000 claims abstract description 3
- 229960004441 tyrosine Drugs 0.000 claims description 12
- 230000020595 eating behavior Effects 0.000 claims description 7
- 235000001130 magnesium glycerophosphate Nutrition 0.000 claims description 6
- 239000011742 magnesium glycerophosphate Substances 0.000 claims description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 6
- BHJKUVVFSKEBEX-UHFFFAOYSA-L magnesium;2,3-dihydroxypropyl phosphate Chemical compound [Mg+2].OCC(O)COP([O-])([O-])=O BHJKUVVFSKEBEX-UHFFFAOYSA-L 0.000 claims description 6
- 240000002900 Arthrospira platensis Species 0.000 claims description 3
- 235000016425 Arthrospira platensis Nutrition 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000008121 dextrose Substances 0.000 claims description 3
- 235000019359 magnesium stearate Nutrition 0.000 claims description 3
- 239000000203 mixture Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 229940082787 spirulina Drugs 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 description 4
- 108010013563 Lipoprotein Lipase Proteins 0.000 description 2
- 102000043296 Lipoprotein lipases Human genes 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 229960002748 norepinephrine Drugs 0.000 description 2
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 240000001987 Pyrus communis Species 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- -1 aromatic amino acid Chemical class 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000002485 combustion reaction Methods 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000004132 lipogenesis Effects 0.000 description 1
- 230000004130 lipolysis Effects 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 230000001483 mobilizing effect Effects 0.000 description 1
- 150000002871 norepinephrines Chemical class 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
COMPLEMENT NUTRITIONNEL ABSORBABLE DESTINE A
FAVORISER L'ELIMINATION DES GRAISSES ET LE REEOUILIBRAGE
DU COMPORTEMENT ALIMENTAIRE.ABSORBABLE NUTRITIONAL SUPPLEMENT FOR
PROMOTE FAT REMOVAL AND REWARMING
FOOD BEHAVIOR.
L'invention concerne un complément nutritionnel absorbable, peros, pour favoriser l'élimination des graisses et le rééquilibrage du comportement alimentaire. The invention relates to an absorbable nutritional supplement, peros, to promote the elimination of fat and the rebalancing of eating behavior.
Comme on le sait, l'accumulation des graisses dans le corps augmente les risques de mortalité ou de complications non-négligeables, notamment en ce qui concerne les maladies cardiovasculaires ou les pathologies articulaires. As we know, the accumulation of fat in the body increases the risk of death or significant complications, especially with regard to cardiovascular diseases or joint pathologies.
L'invention vise à pallier ces inconvénients. Elle concerne un complément nutritionnel absorbable per-os qui favorise l'élimination des graisses, ainsi que le rééquilibrage du comportement alimentaire. The invention aims to overcome these drawbacks. It relates to an absorbable per-bone nutritional supplement which promotes the elimination of fat, as well as the rebalancing of eating behavior.
Ce complément nutritionnel absorbable se caractérise en ce qu'il contient en association de la tyrosine, de la vitamine C et de la vitamine
E, du magnésium et un excipient.This absorbable nutritional supplement is characterized in that it contains in combination with tyrosine, vitamin C and vitamin
E, magnesium and an excipient.
Par "complément nutritionnel", on désigne un ensemble absorbable formant une supplémentation en micronutriments complétant l'alimentation quotidienne, qui permet à la fois d'agir sur un symptôme et en même temps de renforcer l'organisme. By "nutritional supplement" is meant an absorbable whole forming a micronutrient supplementation supplementing the daily diet, which allows both to act on a symptom and at the same time to strengthen the body.
Avantageusement, en pratique, la tyrosine, qui est un amino acide aromatique, se présente sous forme de L-tyrosine. Advantageously, in practice, tyrosine, which is an aromatic amino acid, is in the form of L-tyrosine.
La proportion de vitamine C est égale à la proportion de L- tyrosine et est de l'ordre de trente (30) fois supérieure à celle de la vitamine E, qui sert essentiellement à stabiliser la vitamine C. La vitamine C favorise la transformation de la tyrosine en noradrénaline, qui est responsable de la mobilisation de l'énergie, chaque fois qu'un effort est à fournir ; cette noradrénaline diminue l'activité de la lipoprotéine lipase (LPL), c'est-àdire l'accumulation de graisses dans les tissus adipeux (lipogénèse). The proportion of vitamin C is equal to the proportion of L-tyrosine and is of the order of thirty (30) times greater than that of vitamin E, which essentially serves to stabilize vitamin C. Vitamin C promotes the transformation of tyrosine to norepinephrine, which is responsible for mobilizing energy, whenever an effort is required; this norepinephrine decreases the activity of lipoprotein lipase (LPL), that is to say the accumulation of fat in adipose tissue (lipogenesis).
Le magnésium se présente sous forme de glycérophosphate de magnésium. Ce composé interréagit avec la vitamine C pour activer la synthèse intracellulaire d'AMP cyclique qui, avec l'aide d'autres messagers, va déclencher la lipolyse, c'est-à-dire la mobilisation des graisses stockées dans le tissu adipeux pour les remettre en circulation; ce glycérophosphate de magnésium permet en outre de rééquilibrer le comportement alimentaire en cas de stress. Magnesium is in the form of magnesium glycerophosphate. This compound interacts with vitamin C to activate the intracellular synthesis of cyclic AMP which, with the help of other messengers, will trigger lipolysis, i.e. the mobilization of fat stored in adipose tissue for put back into circulation; this magnesium glycerophosphate also helps rebalance eating behavior in the event of stress.
En d'autres termes, l'association de la tyrosine, de la vitamine C, stabilisée par la vitamine E et du glycérophosphate de magnésium agit en synergie pour favoriser le déstockage des graisses, leur combustion par d'autres tissus, ainsi que le rééquilibrage du comportement alimentaire au niveau de l'appétit et des facteurs qui peuvent le dérégler comme le stress et le fléchissement de l'humeur. In other words, the combination of tyrosine, vitamin C, stabilized by vitamin E and magnesium glycerophosphate acts synergistically to promote the destocking of fats, their combustion by other tissues, as well as rebalancing. eating behavior related to appetite and factors that can upset it, such as stress and mood swings.
Ainsi, le complément nutritionnel caractéristique de l'invention permet, par une sélection de différents composés qui interréagissent entre eux, de régler d'une manière satisfaisante le problème de la surcharge pondérale. Thus, the nutritional supplement characteristic of the invention allows, by a selection of different compounds which interact with each other, to satisfactorily resolve the problem of overweight.
Comme excipient, on utilise avantageusement du dextrose stabilisé par du stéarate de magnésium, éventuellement coloré par la poudre de spiruline. As excipient, use is advantageously made of dextrose stabilized with magnesium stearate, optionally colored with spirulina powder.
Dans une forme de réalisation avantageuse, l'association caractéristique de l'invention contient en pour cent en poids:
- 30,91 % de L-tyrosine;
- 30,91 % de vitamine C;
- 24,18 % de glycérophosphate de magnésium;
- 0,91 % de vitamine E à 50 % dans un mélange de gélatine et de
dextrine;
- 13,09 % d'excipient, par exemple:
10,59 % de dextrose;
1,5 % d'un colorant spiruline en poudre;
1 % de stéarate de magnésium.In an advantageous embodiment, the characteristic association of the invention contains in percent by weight:
- 30.91% L-tyrosine;
- 30.91% vitamin C;
- 24.18% magnesium glycerophosphate;
- 0.91% vitamin E at 50% in a mixture of gelatin and
dextrin;
- 13.09% of excipient, for example:
10.59% dextrose;
1.5% of a powdered spirulina dye;
1% magnesium stearate.
Pour garantir l'intégrité des différents composés, on effectue avantageusement la formulation de la manière suivante. Dans un premier temps, on granule en phase humide les excipients et les principaux composés. Puis, dans un deuxième temps, on mélange en phase sèche les vitamines et les principes actifs fragiles. To guarantee the integrity of the various compounds, the formulation is advantageously carried out in the following manner. Initially, the excipients and the main compounds are granulated in the wet phase. Then, in a second step, vitamins and fragile active ingredients are mixed in the dry phase.
Le complément nutritionnel conforme à l'invention peut être absorbé sous forme de poudre, de gélules, de granules, et avantageusement de comprimés. The nutritional supplement according to the invention can be absorbed in the form of powder, capsules, granules, and advantageously tablets.
Ce complément nutritionnel, sous forme de comprimés de 550 mg, peut être avalé à raison de quatre comprimés avant le déjeuner pendant trois à six mois renouvelable. This nutritional supplement, in the form of 550 mg tablets, can be swallowed at the rate of four tablets before lunch for three to six months, renewable.
Ce complément nutritionnel permet comme déjà dit de favoriser l'élimination des graisses, ainsi que le rééquilibrage du comportement alimentaire. This nutritional supplement allows, as already said, to promote the elimination of fat, as well as the rebalancing of eating behavior.
Claims (6)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305321A FR2704396B1 (en) | 1993-04-29 | 1993-04-29 | Absorbable nutritional supplement intended to promote the elimination of fats and the rebalancing of eating behavior. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR9305321A FR2704396B1 (en) | 1993-04-29 | 1993-04-29 | Absorbable nutritional supplement intended to promote the elimination of fats and the rebalancing of eating behavior. |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2704396A1 true FR2704396A1 (en) | 1994-11-04 |
| FR2704396B1 FR2704396B1 (en) | 1995-06-02 |
Family
ID=9446749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR9305321A Expired - Fee Related FR2704396B1 (en) | 1993-04-29 | 1993-04-29 | Absorbable nutritional supplement intended to promote the elimination of fats and the rebalancing of eating behavior. |
Country Status (1)
| Country | Link |
|---|---|
| FR (1) | FR2704396B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758440A1 (en) * | 1997-01-21 | 1998-07-24 | Eric Marcel Jean Baseilhac | New food supplement to assist weight loss containing oligo- and polysaccharide(s) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4973467A (en) * | 1989-10-13 | 1990-11-27 | Natrol, Inc. | Dietary supplement for adults |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
-
1993
- 1993-04-29 FR FR9305321A patent/FR2704396B1/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0087068A1 (en) * | 1982-02-12 | 1983-08-31 | Thomas Moses Dr. Beck | Nutritional supplement |
| US4973467A (en) * | 1989-10-13 | 1990-11-27 | Natrol, Inc. | Dietary supplement for adults |
| WO1993002682A1 (en) * | 1991-08-06 | 1993-02-18 | Labco Pharmaceuticals, Inc. | Method and compositions for reducing craving for alcohol and stimulants |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2758440A1 (en) * | 1997-01-21 | 1998-07-24 | Eric Marcel Jean Baseilhac | New food supplement to assist weight loss containing oligo- and polysaccharide(s) |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2704396B1 (en) | 1995-06-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Snyderman et al. | The plasma aminogram. I. Influence of the level of protein intake and a comparison of whole protein and amino acid diets | |
| US6479545B1 (en) | Formulation for menopausal women | |
| EP1009416A1 (en) | Weight control composition comprising hypericum perforatum | |
| Houston | The role of nutrition, nutraceuticals, vitamins, antioxidants, and minerals in the prevention and treatment of hypertension | |
| SK12398A3 (en) | Two-stage preparation | |
| JP2002121145A (en) | Xanthine oxidase inhibitor | |
| FR2704390A1 (en) | Nutritional supplement which can be taken by mouth, intended for improving the skin | |
| FR2704393A1 (en) | Nutritional supplement which can be taken orally to optimise growth and maintain robustness of bones | |
| EP1093817B1 (en) | Composition containing compounds with adrenergic activity and vegetable extracts of crataegus and gingko biloba for the treatment of overweight and obesity | |
| FR2704396A1 (en) | Nutritional supplement which can be taken orally, intended for promoting the elimination of fats and the restoration of balanced nutritional behaviour | |
| Pretorius et al. | An assessment of nutritive value of fish flour in the treatment of convalescent kwashiorkor patients | |
| FR2704392A1 (en) | Nutritional supplement which can be taken orally to improve and optimise individuals' levels of physical and mental activity | |
| HU229061B1 (en) | Antioxidant composition comprising propionyl l-carnitine and a flavonoid against thrombosis and atherosclerosis | |
| Klatz | The Official Anti-Aging Revolution: Stop the Clock Time is on Your Side for a Younger, Stronger, Happier You | |
| JP2001261569A (en) | Antiobestic agent | |
| EA027252B1 (en) | Biologically active food additive for preventing cardiovascular diseases and enhancing the cardiovascular system | |
| FR2704394A1 (en) | Nutritional supplement which can be taken orally for the treatment of hair and nails | |
| CA3086386A1 (en) | Dietary supplements and use thereof on menses | |
| FR2880541A1 (en) | Composition, for use as a complement to food phytotherapy, comprises a specific extract of plants (e.g. blackcurrant fruit, acerola, ginseng, guarana and wrack) and xylitol | |
| EP1010429B1 (en) | Pharmaceutical composition, in particular for dietetical use comprising a derivative of pyruvic acid and unripe bitter orange extract | |
| FR2704395A1 (en) | Nutritional supplement which can be taken by mouth, intended for improving mental activity | |
| CN107156859B (en) | A food containing short peptide for patients with cardiovascular and cerebrovascular diseases | |
| JP2002034507A (en) | Health assisting food | |
| WO2023006857A1 (en) | Combination product for stimulating liver cell function and promoting sleep | |
| FR2623397A1 (en) | Plant-based medicinal composition for internal use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ST | Notification of lapse |